

WHAT IS CLAIMED IS:

a 1. A method for treating Parkinson's disease *consisting essentially of* comprising administering to a patient suffering from Parkinson's disease an effective amount of at least one cholinesterase inhibitor.

2. The method according to claim 1 wherein the cholinesterase inhibitor is an acetylcholinesterase inhibitor.

3. The method according to claim 2 wherein the acetylcholinesterase inhibitor is selected from the group consisting of galanthamine, physostigmine, tetrahydroaminoacridine (tacrine), citicoline, velnacrine maleate, metrifonate, and neptastigmine.

4. The method according to claim 1 wherein the cholinesterase inhibitor is a butyrylcholinesterase inhibitor.

5. The method according to claim 1 wherein the at least one cholinesterase inhibitor is administered in combination with levodopa.

6. The method according to claim 1 wherein the at least one cholinesterase inhibitor is administered in an amount of from about 20 mg to about 200 mg per day.

7. The method according to claim 1 further comprising administering levodopa to said patient in combination with said cholinesterase inhibitor.

8. The method according to claim 1 wherein the patient suffering from Parkinson's disease suffers from parkinsonian dementia.

Add  
A' 7

add  
B' 7